Singapore markets close in 6 hours 17 minutes

CStone Pharmaceuticals (2616.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
1.320-0.050 (-3.65%)
As of 10:27AM HKT. Market open.
Full screen
Loading interactive chart…
  • PR Newswire

    CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates

    CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2023 annual results and recent business updates.

  • PR Newswire

    CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer

    CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the National Medical Products Administration (NMPA) of China has approved the supplemental biologics license application (sBLA) for sugemalimab (Cejemly®) in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment for unresectabl

  • PR Newswire

    CStone sells to Servier its exclusive rights to TIBSOVO® in Greater China and Singapore

    CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Servier, a global independent pharmaceutical group, today announced an agreement whereby Servier acquires from CStone the exclusive rights to develop and commercialize TIBSOVO® (ivosidenib tablets) in Greater China and Singapore.